Ocera Therapeutics
Biopharmaceutical company developing novel therapeutics for patients with acute and chronic liver diseases
About Ocera Therapeutics
Ocera Therapeutics, Inc. was a clinical-stage biopharmaceutical company that concentrated on creating treatments for liver diseases. The company was founded in 2005 and operated from Redwood City, California. A significant event in the company's history was the merger with Tranzyme, Inc. in July 2013, after which the combined entity continued under the Ocera Therapeutics name, led by President and CEO Linda S. Grais, MD. This merger was followed by a $20 million private placement from several venture capital firms. The company's journey culminated in its acquisition by Mallinckrodt plc, a deal announced in November 2017 and finalized in December 2017. Mallinckrodt acquired Ocera for an initial $42 million, with potential for an additional $75 million based on development and sales milestones. Following the acquisition, Ocera became an indirect, wholly-owned subsidiary of Mallinckrodt and ceased to be a publicly traded company on the Nasdaq exchange.
Ocera's business model was centered on the development and eventual commercialization of its lead drug candidate, OCR-002 (ornithine phenylacetate), targeting orphan and other serious liver diseases with high unmet medical need. The company's market focus was on patients with hepatic encephalopathy (HE), a neuropsychiatric complication of acute or chronic liver disease caused by high ammonia levels (hyperammonemia). The potential U.S. market for HE was estimated to be substantial, with around 200,000 hospitalizations annually.
The company's core product, OCR-002, is an ammonia scavenger designed to lower dangerously high ammonia levels in the blood. It functions through a dual-mode action that does not rely on the liver, which is compromised in these patients. Once administered, OCR-002 breaks down into ornithine and phenylacetate. Ornithine helps convert ammonia into glutamine in the muscles, and phenylacetate combines with this glutamine to form phenylacetylglutamine, which is then excreted by the kidneys. This mechanism provides an alternative pathway for ammonia removal. OCR-002 was developed in both an intravenous (IV) formulation for acute HE in hospitalized patients and an oral version for maintenance therapy to prevent recurrence. The U.S. FDA had granted OCR-002 both Orphan Drug designation and Fast Track status. Despite a Phase 2b trial not meeting its primary endpoint, the drug demonstrated a significant effect on lowering ammonia levels, prompting Mallinckrodt to acquire it with the belief that trial design, not the drug itself, was the issue.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2011
- Open positions
- None listed
- Dealroom signal
- 20.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Nov 2017 | $42M | $42M | Mallinckrodt | — |
| POST IPO DEBTDebt | Aug 2015 | $20M | — | Greenspring Associates · Silicon Valley Bank · Oxford Finance | — |
Growth signals
Latest recorded traffic for Ocera Therapeutics is 240 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Ocera Therapeutics in the Palo Alto ecosystem
The Ocera Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Sofinnova Investments
Domain Associates
Thomas McNerney & Partners
Series B and later15 investors entered at this stage
Greenspring Associates
CDIB BioScience Ventures
GeneChem- WAWasatch Advisors
Cross Creek
FinTech Innovation Lab
Deerfield Partners
RA Capital Management
Venrock
Great Point Partners
Three Arch Partners
InterWest Partners
Vivo Capital
Silicon Valley Bank
Oxford Finance
Other known investors2 additional known investors
Mallinckrodt
Redmont Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ocera Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ocera Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









